Payment overview · 2025
General Payments
$1,753.06
57 reported records · 23 companies
Healthcare provider profile · identity verified
John Arthur Muenz, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · JACKSONVILLE, FL · NPI 1811030430
Verified facts
What the public records show
CMS Open Payments records show John Arthur Muenz, M.D. received $1,753.06 in general payments during 2025 across 57 reported records.
CeQur Corporation accounted for 11.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Kerendia, Mounjaro, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| CeQur Corporation | Unresolved — no canonical attribution shown | $200.02 | 11.4% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $196.06 | 11.2% | 9 | 2025 |
| Ethicon Inc. | Unresolved — no canonical attribution shown | $188.86 | 10.8% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $164.65 | 9.4% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $149.02 | 8.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $116.85 | 6.7% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $114.44 | 6.5% | 6 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $89.62 | 5.1% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $75.34 | 4.3% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $54.33 | 3.1% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $53.94 | 3.1% | 3 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $50.10 | 2.9% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $42.74 | 2.4% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $41.96 | 2.4% | 2 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $39.60 | 2.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $37.19 | 2.1% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $29.15 | 1.7% | 2 | 2025 |
| Verrica Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $24.58 | 1.4% | 1 | 2025 |
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $24.36 | 1.4% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.42 | 1.3% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $17.62 | 1.0% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $13.77 | 0.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $5.44 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,753.06 | 57 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $200.02 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $196.06 | 9 | 2025 |
Source payment records
|
|||||
| Monarch Platform Normalized: monarch platform |
Device | Ethicon Inc. | $188.86 | 1 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $164.65 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $114.44 | 6 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $89.62 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $83.45 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $75.34 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $75.34 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $53.94 | 3 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $50.10 | 2 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Optinose US, Inc., Paratek Pharmaceuticals, Inc. | $47.78 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $41.96 | 2 | 2025 |
Source payment records
|
|||||
| Extended Holter Normalized: extended holter |
Device | Philips North America LLC | $39.60 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $33.40 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $29.15 | 2 | 2025 |
Source payment records
|
|||||
| YCANTH Normalized: ycanth |
Drug | Verrica Pharmaceuticals Inc. | $24.58 | 1 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $23.48 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $23.42 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $23.00 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $19.86 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $19.26 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $17.62 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $17.33 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.11 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $13.77 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $5.44 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 56 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
56 | 17 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
56 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
77 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 127 | 42 |
| Amlodipine Besylate | Amlodipine Besylate | 117 | 38 |
| Lisinopril | Lisinopril | 94 | 33 |
| Losartan Potassium | Losartan Potassium | 94 | 30 |
| Metformin Hcl | Metformin Hcl | 93 | 36 |
| Methylprednisolone | Methylprednisolone | 89 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 82 | 33 |
| Ozempic | Semaglutide | 77 | 14 |
| Atorvastatin Calcium | Atorvastatin Calcium | 69 | 29 |
| Omeprazole | Omeprazole | 69 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 59 | 19 |
| Jardiance | Empagliflozin | 56 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 53 | 19 |
| Pantoprazole Sodium | Pantoprazole Sodium | 49 | 19 |
| Trazodone Hcl | Trazodone Hcl | 49 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 47 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 46 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 43 | 24 |
| Gabapentin | Gabapentin | 38 | 14 |
| Potassium Chloride | Potassium Chloride | 38 | 14 |
| Azithromycin | Azithromycin | 37 | 21 |
| Carvedilol | Carvedilol | 35 | suppressed |
| Simvastatin | Simvastatin | 35 | 14 |
| Eliquis | Apixaban | 34 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 31 | suppressed |
| Mounjaro | Tirzepatide | 31 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 30 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 12 |
| Alendronate Sodium | Alendronate Sodium | 28 | 13 |
| Clonazepam | Clonazepam | 28 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | 11 |
| Prednisone | Prednisone | 28 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 27 | suppressed |
| Fluconazole | Fluconazole | 27 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 25 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 25 | 12 |
| Anastrozole | Anastrozole | 24 | suppressed |
| Pregabalin | Pregabalin | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 12 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 23 | suppressed |
| Glipizide | Glipizide | 22 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 22 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Olanzapine | Olanzapine | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 20 | suppressed |
| Alprazolam | Alprazolam | 19 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 19 | suppressed |
| Eszopiclone | Eszopiclone | 19 | suppressed |
| Bumetanide | Bumetanide | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Furosemide | Furosemide | 17 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 16 | suppressed |
| Famotidine | Famotidine | 15 | suppressed |
| Allopurinol | Allopurinol | 14 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Spironolactone | Spironolactone | 14 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 13 | suppressed |
| Enbrel Mini | Etanercept | 13 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 13 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Kerendia | Finerenone | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Meloxicam | Meloxicam | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 11 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 11 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,753.06 · 57 records | CeQur Corporation | AIRSUPRA, APTIMA, AREXVY, Auvelity, BREZTRI, CAPLYTA, CeQur Simplicity, Cologuard Collection Kit, Extended Holter, FANAPT, JARDIANCE, Kerendia, Korlym, MOUNJARO, Monarch Platform, NUZYRA, QULIPTA, SAPIEN 3 Ultra RESILIA, SUBLOCADE, Sunosi, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, XHANCE, YCANTH, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error